Amneal Pharmaceuticals received approval for its abbreviated new drug application for the drug in six strengths — 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg — according to a Feb. 19 news release from the drugmaker.
Some common adverse reactions associated with the drug, which is used to treat certain blood cancers, include neutropenia, thrombocytopenia and leukopenia.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
